DALFAMPRIDINE (dalfampridine) by Teva is potassium channel antagonists [moa]. Approved for walking in adult patients with multiple sclerosis (ms), multiple sclerosis. First approved in 2017.
Drug data last refreshed 19h ago
Potassium Channel Antagonists
Potassium Channel Blocker
Worked on DALFAMPRIDINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dalfampridine for Imbalance in Multiple Sclerosis